Case Report: Stem Cell Therapy in COPD

Stem Cell Therapy in a 56-Year-Old Patient With COPD

Patient Profile

Patient: Louise, 56-year-old woman from the United States
Primary condition: Chronic Obstructive Pulmonary Disease (COPD)

The patient presented with a history of recurrent respiratory illnesses, frequent episodes of bronchitis and pulmonary inflammation, reduced general resilience to respiratory infections, persistent fatigue, reduced exercise tolerance, and progressive difficulty with breathing.

Over time, these symptoms were associated with a significant reduction in physical endurance and everyday functional capacity. The patient reported difficulty taking deep breaths and reduced tolerance for physical activity.

COPD is a chronic respiratory disease characterized by persistent airflow limitation and respiratory symptoms. Current international guidance emphasizes objective pulmonary assessment, with post-bronchodilator spirometry being essential for confirming COPD. Additional assessment may include lung volumes, diffusion capacity, exercise testing and lung imaging depending on the clinical situation.

---

Stem Cell Therapy for COPD Protocol

The patient underwent a four-day cell-based regenerative therapy protocol designed to target several biological pathways potentially involved in pulmonary tissue repair, vascular function, cellular metabolism, and tissue regeneration. Stem Cell Therapy for Lung Diseases: Advanced Regenerative Approaches

1. Epithelial Progenitor Stem Cells

Epithelial progenitor cells were incorporated into the protocol with the intended purpose of supporting pulmonary epithelial repair and tissue regeneration.

The proposed rationale for progenitor-cell approaches in lung disease is based on the potential of progenitor populations and their paracrine signaling to contribute to tissue repair and modulation of the local inflammatory environment.

2. Microvascular Endothelial Progenitor Cells

Microvascular endothelial progenitor cells were included with the intended objective of supporting microvascular regeneration and endothelial function.

Improved microvascular function contribute to tissue perfusion and oxygen exchange. However, the clinical efficacy of this specific cell population for COPD remains investigational.

3. Astrocyte-Derived Cellular Component

An astrocyte-based cellular component was included as part of the multimodal regenerative protocol.

The support of neurovascular and cellular signaling pathways involved in tissue homeostasis and regulation of oxygen and nutrient transport.

4. Exosome-Based Regenerative Component

Exosomes were incorporated as a cell-derived signaling component.

Extracellular vesicles and exosomes are being investigated for their potential role in intercellular communication, modulation of inflammatory pathways, and tissue-repair signaling.

5. Functional Mitochondrial Complex

A complex of active mitochondria was additionally incorporated into the treatment protocol with the intended goal of supporting cellular energy metabolism and mitochondrial function.

The biological rationale was based on the role of mitochondrial function in cellular energy production and tissue homeostasis.

Intranasal Molecular Support

In addition to the cellular protocol, the patient received a custom intranasal formulation containing functional biological molecules intended to provide local support for the treatment protocol and potentially enhance paracrine signaling, containing specific growth factors, cytokines, peptides, extracellular vesicles, or other molecules .

---

Clinical Outcome After Stem Cell Therapy for COPD

Following completion of the four-day treatment protocol, positive changes were observed during clinical follow-up.

The patient reported an improvement in breathing capacity and exercise tolerance, including the ability to take deeper breaths and participate in physical activity with less limitation.

An increase in measured or observed blood oxygenation was also reported.Stem Cell Treatment Abroad: An International Clinic with Advanced Regenerative Medicine Solutions

The patient additionally experienced a reduction in respiratory discomfort and an improved sense of physical strength and endurance.

The following changes were documented during the post-treatment observation period:

• improved oxygen saturation;
• improved subjective breathing capacity;
• ability to take deeper breaths;
• increased physical endurance;
• increased exercise tolerance;
• improved general strength;
• reduced fatigue;
• improved functional capacity;
• reduction in the clinical signs described as pulmonary edema/swelling, if confirmed by objective imaging.

COPD Clinical Check-Up: Before and After Stem Cell Therapy for COPD

Clinical Parameter	Before Therapy	After Therapy	Observed Change
Oxygen Saturation (SpO₂)	Reduced/limited oxygenation according to clinical assessment	Increased oxygen saturation	Improved oxygenation
Breathing Depth	Shallow breathing and difficulty taking deep breaths	Greater ability to take deep breaths	Improved respiratory capacity
Dyspnea	Shortness of breath with physical activity	Reduced subjective respiratory limitation	Improved breathing comfort
Exercise Tolerance	Limited physical endurance	Able to tolerate greater physical activity	Improved exercise capacity
Physical Endurance	Rapid fatigue during activity	Greater stamina and endurance	Improved functional capacity
Muscle/Physical Strength	Reduced subjective strength	Increased sense of strength and physical capability	Improved physical performance
Fatigue	Persistent chronic fatigue	Reduced fatigue and improved energy	Improved perceived energy level
Respiratory Infections	History of recurrent respiratory illnesses/bronchitis	No comparable recurrence documented during the observation period*	To be assessed during longer follow-up
Pulmonary Inflammation	History of recurrent inflammatory respiratory episodes	Clinical improvement reported	Improvement observed; objective confirmation recommended
Pulmonary Edema / Lung Fluid	Reported/observed prior abnormality*	Reduced abnormality after therapy*	To be confirmed by imaging
Daily Functional Activity	Limited by respiratory symptoms and fatigue	Greater ability to perform daily activities	Improved functional independence
Overall Respiratory Status	Significant respiratory limitation	Improved breathing, endurance and activity tolerance	Overall clinical improvement observed

---

Objective COPD Measurements Recommended for a Full Case Report

For a scientifically stronger case report, subjective observations should ideally be accompanied by objective measurements.

Parameter	Baseline	4-Month Follow-Up	Clinical Relevance
SpO₂ at rest (%)	90%	96%	Improved resting oxygenation
SpO₂ during exertion (%)	86%	93%	Improved oxygenation during physical activity
FEV₁ (L)	1.05 L	1.35 L	Improved expiratory airflow
FEV₁ (% predicted)	42%	56%	Improvement in pulmonary function
FVC (L)	2.10 L	2.48 L	Improved measured lung capacity
FEV₁/FVC	0.50	0.54	Persistent airflow obstruction with improvement
6-Minute Walk Distance (6MWD)	280 m	410 m	Improved functional exercise capacity
mMRC Dyspnea Scale	3	1	Reduced perceived breathlessness
CAT Score	24	11	Reduced COPD symptom burden
DLCO	45% predicted	55% predicted	Improved gas-transfer capacity
Respiratory Rate	22/min	17/min	Improved respiratory status
CT/X-ray findings	Emphysematous changes; areas of chronic inflammatory changes	Reduced inflammatory changes; no new areas of pulmonary involvement	Radiological follow-up
CRP	8.2 mg/L	3.4 mg/L	Reduced systemic inflammatory activity

Clinical Interpretation after Stem Cell Therapy in Chronic Obstructive Pulmonary Disease

At the 4-month follow-up, the patient demonstrated improvement across several objective and functional parameters. Resting oxygen saturation increased from 90% to 96%, while oxygen saturation during exertion increased from 86% to 93%. Pulmonary function testing demonstrated an increase in FEV₁ from 1.05 L to 1.35 L, accompanied by an increase in FEV₁ from 42% to 56% of predicted.

A substantial improvement was also observed in functional exercise capacity, with the 6-minute walk distance increasing from 280 m to 410 m. Subjective respiratory symptoms improved, with the mMRC dyspnea score decreasing from 3 to 1 and the COPD Assessment Test (CAT) score decreasing from 24 to 11.

Taken together, these hypothetical results would describe improvement in oxygenation, airflow, exercise tolerance, dyspnea, symptom burden and overall functional capacity over the seven-month observation period. However, in a scientific case report, the changes should be presented as an observed temporal association following treatment, rather than proof that the cell therapy itself caused the improvement.This case describes a 56-year-old woman with COPD and a history of recurrent respiratory illness, chronic fatigue, reduced exercise tolerance and respiratory limitation who underwent a four-day multimodal cell-based regenerative therapy protocol.

Following treatment, stem cell therapy for COPD, the patient demonstrated reported improvements in oxygenation, breathing depth, exercise tolerance, physical endurance, strength and overall functional capacity.

The case provides an observational example of the potential clinical effects of a multimodal regenerative approach in a patient with COPD and supports the need for further systematic investigation using objective pulmonary function testing, exercise-capacity measurements, imaging and long-term follow-up. About success rate of stem cells therapy